Insider · CIK 0001612095

Haqq Christopher

Reports to the SEC for 3 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001612095

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-16	ELTXElicio Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+64.6K sh	—	—	64,643
2026-02-02	ELTXElicio Therapeutics, Inc.A Award	See Remarks	AAward	+25.4K sh	—	—	57,381
2026-02-02	ELTXElicio Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+50.9K sh	—	—	50,900
2025-02-03	ELTXElicio Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+44K sh	—	—	44,000
2024-09-30	ELTXElicio Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+28.2K sh	—	—	28,200
2024-02-01	ELTXElicio Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+28.2K sh	—	—	28,200
2021-08-11	SRZNSurrozen, Inc./DEA Award	Former Director	AAward	+30K sh	—	—	30,000
2021-08-11	SRZNSurrozen, Inc./DE · Class B Ordinary SharesD Disposition to Issuer	Former Director	DDisposition to Issuer	−30K sh	—	—	0
2019-02-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−775 sh	$39.59	−$30.7K	271,943
2019-02-11	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−14K sh	$38.55	−$539K	272,718
2019-02-06	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−2,677 sh	$38.04	−$102K	282,903
2019-02-06	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−9,698 sh	$38.78	−$376K	273,205
2019-02-06	ATRAAtara Biotherapeutics, Inc.F Tax Payment	EVP, R&D & Chief Scientific Of	FTax Payment	−1,512 sh	$38.47	−$58.2K	271,693
2019-02-06	ATRAAtara Biotherapeutics, Inc.A Award	EVP, R&D & Chief Scientific Of	AAward	+15K sh	—	—	286,693
2019-02-06	ATRAAtara Biotherapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	EVP, R&D & Chief Scientific Of	AAward	+30K sh	—	—	30,000
2018-11-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−775 sh	$33.81	−$26.2K	285,580
2018-09-26	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−13.5K sh	$43.08	−$582K	286,355
2018-09-25	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−10K sh	$40.26	−$403K	303,355
2018-09-25	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−3,500 sh	$41.23	−$144K	299,855
2018-09-24	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−14.1K sh	$39.74	−$559K	317,286
2018-09-24	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−3,931 sh	$40.53	−$159K	313,355
2018-08-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−775 sh	$37.54	−$29.1K	331,355
2018-05-15	ATRAAtara Biotherapeutics, Inc.M Exercise/Conversion	EVP, R&D & Chief Scientific Of	MExercise/Conversion	+25K sh	$11.00	+$275K	357,905
2018-05-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−6,885 sh	$44.44	−$306K	351,020
2018-05-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−9,638 sh	$45.21	−$436K	341,382
2018-05-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−9,252 sh	$46.02	−$426K	332,130
2018-05-15	ATRAAtara Biotherapeutics, Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	EVP, R&D & Chief Scientific Of	MExercise/Conversion	−25K sh	—	—	25,000
2018-03-26	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−17.2K sh	$39.76	−$685K	334,005
2018-03-26	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−1,100 sh	$40.29	−$44.3K	332,905
2018-02-15	ATRAAtara Biotherapeutics, Inc.M Exercise/Conversion	EVP, R&D & Chief Scientific Of	MExercise/Conversion	+553 sh	—	—	351,232
2018-02-15	ATRAAtara Biotherapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP, R&D & Chief Scientific Of	MExercise/Conversion	−553 sh	—	—	0
2018-02-09	ATRAAtara Biotherapeutics, Inc.F Tax Payment	EVP, R&D & Chief Scientific Of	FTax Payment	−4,925 sh	$41.70	−$205K	350,679
2018-02-06	ATRAAtara Biotherapeutics, Inc.A Award	EVP, R&D & Chief Scientific Of	AAward	+17.5K sh	—	—	360,030
2018-02-06	ATRAAtara Biotherapeutics, Inc.F Tax Payment	EVP, R&D & Chief Scientific Of	FTax Payment	−4,426 sh	$35.80	−$158K	355,604
2018-02-06	ATRAAtara Biotherapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	EVP, R&D & Chief Scientific Of	AAward	+35K sh	—	—	35,000
2017-11-15	ATRAAtara Biotherapeutics, Inc.M Exercise/Conversion	EVP, R&D & Chief Scientific Of	MExercise/Conversion	+829 sh	—	—	344,134
2017-11-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−1,604 sh	$13.36	−$21.4K	342,530
2017-11-15	ATRAAtara Biotherapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP, R&D & Chief Scientific Of	MExercise/Conversion	−829 sh	—	—	553
2017-10-16	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−6,000 sh	$14.35	−$86.1K	343,305
2017-09-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−6,000 sh	$15.30	−$91.8K	349,305
2017-08-15	ATRAAtara Biotherapeutics, Inc.M Exercise/Conversion	EVP, R&D & Chief Scientific Of	MExercise/Conversion	+829 sh	—	—	362,909
2017-08-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−7,604 sh	$14.75	−$112K	355,305
2017-08-15	ATRAAtara Biotherapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP, R&D & Chief Scientific Of	MExercise/Conversion	−829 sh	—	—	1,382
2017-07-17	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−6,000 sh	$14.92	−$89.5K	362,080
2017-06-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−6,000 sh	$12.65	−$75.9K	368,080
2017-05-15	ATRAAtara Biotherapeutics, Inc.M Exercise/Conversion	EVP, R&D & Chief Scientific Of	MExercise/Conversion	+829 sh	—	—	381,684
2017-05-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−7,604 sh	$14.99	−$114K	374,080
2017-05-15	ATRAAtara Biotherapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP, R&D & Chief Scientific Of	MExercise/Conversion	−829 sh	—	—	2,211
2017-04-17	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−6,000 sh	$17.28	−$104K	380,855
2017-03-15	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, R&D & Chief Scientific Of	SSale	−6,000 sh	$19.60	−$118K	386,855

Recent filings

Accepted (ET)
Jul 174
Haqq Christopher0001612095-26-000002
SEC(opens sec.gov)
Feb 34
Haqq Christopher0001601485-26-000002
SEC(opens sec.gov)
Feb 44
Haqq Christopher0001601485-25-000014
SEC(opens sec.gov)
Oct 24
Haqq Christopher0001601485-24-000049
SEC(opens sec.gov)
Feb 54
Haqq Christopher0001140361-24-005497
SEC(opens sec.gov)
Aug 134
Haqq Christopher0000899243-21-033040
SEC(opens sec.gov)
Feb 194
Haqq Christopher0001209191-19-011187
SEC(opens sec.gov)
Feb 114
Haqq Christopher0001209191-19-009116
SEC(opens sec.gov)
Feb 84
Haqq Christopher0001209191-19-008526
SEC(opens sec.gov)
Nov 154
Haqq Christopher0001209191-18-058763
SEC(opens sec.gov)
Sep 274
Haqq Christopher0001209191-18-052465
SEC(opens sec.gov)
Sep 254
Haqq Christopher0001209191-18-052162
SEC(opens sec.gov)

Companies

Address

C/O ELICIO THERAPEUTICS, INC. 451 D STREET, 5TH FLOOR, SUITE 501

BOSTON, MA, 02210